Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
8 y) [" b% b. y. ^0 h3 xNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 ' a) m7 r! \. O! T
+ Author Affiliations- c5 j+ X% I9 j) Q# C
A9 q& T2 L: K" }+ J: U* W$ R
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
& ?1 F4 Z) S1 L0 g7 e8 I7 H4 ^2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 6 E; w- e3 d' s; J6 E+ n% n
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
0 ~( b, l+ z r% M5 p' p3 u' v4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan / o; Z I5 Z% p: X. H$ ?4 i, Z
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
/ A$ z7 g5 {4 D: b& Q7 z, [0 @6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
* M2 x6 G/ h9 i0 i6 y7Kinki University School of Medicine, Osaka 589-8511, Japan , b# x) M4 N) a8 k
8Izumi Municipal Hospital, Osaka 594-0071, Japan
' ^/ a) }6 p: w ]9 i; O9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
. b, l5 b3 Z6 i5 d6 d' M( KCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp - U- K& |! D: N3 e7 V
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. , [" F' [/ _9 D5 _+ L6 ]
! R+ i3 r$ G. T4 d4 ?1 z) n: v
|